Sabby Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sabby Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-35,000	Closed	-$1.11M	–	194
2020 Q4	$1.11M	Sell	35,000 -80,000	-70%	-$2.1M	0.21%	47
2020 Q3	$2.95M	Buy	+115,000	New	+$2.62M	0.44%	33
2016 Q4	–	Sell	-14,800	Closed	-$209K	–	332
2016 Q3	$226K	Sell	14,800 -57,143	-79%	-$2.31M	0.01%	270
2016 Q2	$2.79M	Sell	71,943 -6,057	-8%	-$218K	0.15%	87
2016 Q1	$2.17M	Buy	+78,000	New	+$2.6M	0.11%	92
2015 Q2	–	Sell	-100,000	Closed	-$2.54M	–	364
2015 Q1	$2.39M	Buy	+100,000	New	+$2.24M	0.1%	131

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Sabby Management's ITCI Position: Q1 2021 in Review

Sabby Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2021, closing a stake of 35,000 shares — an estimated $1.11M sold.

Sabby Management first reported a position in ITCI in Q1 2015 and held it in 6 quarters. The position peaked at $2.95M in Q3 2020. 170 funds tracked by Wall St. Rank hold ITCI as of Q1 2021.

Sabby Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2021 after selling out during the quarter.
Sabby Management sold 35,000 Intra-Cellular Therapies Inc. shares in Q1 2021, an estimated $1.11M.
Sabby Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 6 quarters.
Sabby Management's Intra-Cellular Therapies Inc. position peaked at $2.95M in Q3 2020.
170 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.